Bilaal.Raja
Company record

ORGO  Organogenesis Holdings Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$222m
Revenue TTM
$458m
Net income TTM
$-84m
Free cash flow
$21m
Composite score
66.4
Sector rank
#2823

Valuation

P / E
EV / EBITDA
EV / sales
0.4
FCF yield
9.39%
Yield vs 10-yr
-42.66pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-18.4%
EBITDA margin
-4.4%
ROE
-56.8%
ROIC
-35.1%
Revenue growth
6.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

While the longer-term impact of CMS’ updated 2026 Medicare reimbursement changes is still uncertain, we experienced a significant year-over-year decline in revenue in the first and second quarters of fiscal year 2026, and we are continuing to experience a significant year-over-year decline in revenue in the third quarter of fiscal year 2026. Dermagraft As previously disclosed, manufacturing of Dermagraft was suspended in the fourth quarter of 2021 and sales of Dermagraft were suspended in the second quarter of 2022. …Organogenesis Holdings Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →